Evidence map›Paper›PMID 27028342›Full record

ArticleJournal of proteome research2016

Evaluation of the mirn23a Cluster through an iTRAQ-based Quantitative Proteomic Approach.

Katelyn R Ludwig, Richard Dahl, Amanda B Hummon

Abstract read
In one paragraph

Article in Journal of proteome research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Katelyn R LudwigHarper Cancer Research Institute, University of Notre Dame , Notre Dame, Indiana 46617 United States.
Richard DahlHarper Cancer Research Institute, University of Notre Dame , Notre Dame, Indiana 46617 United States.
Amanda B HummonHarper Cancer Research Institute, University of Notre Dame , Notre Dame, Indiana 46617 United States.
University of Notre Dame · USIndiana University · US

Funding

Spatial SILAC: Examining the Proteome in 3D Cell CulturesR01GM110406 · NIGMS · UNIVERSITY OF NOTRE DAME · PI HUMMON, AMANDA B. · 2014 to 2022
$3.0M
NIGMS NIH HHS R01 GM110406
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression that are implicated in a number of disease states. MiRNAs can exist as individual entities or may be clustered and transcribed as a single polycistron. The mirn23a cluster consists of three miRNAs: miR-23a, miR-24-2, and miR-27a. Although these miRNAs are transcribed together, they often exist at varying levels in the cell. Despite the fact that the mirn23a cluster is known to play a role in a number of diseases and developmental processes, few direct targets have been identified. In this study, we examined the effects of miR-23a, miR-24-2, miR-27a, or the mirn23a cluster overexpression on the proteome of 70Z/3 pre-B lymphoblast cells. Quantitative mass spectrometry using isobaric tags for relative and absolute quantification (iTRAQ) allowed for the global profiling of cell lines after miRNA overexpression. We identified a number of targets of each miRNA that contained predicted miRNA seed sequences and are likely direct targets. In addition, we discovered a cohort of shared miRNA targets and cluster targets, demonstrating the importance of studying miRNA clusters in their entirety.

Indexed as

Cell LineGene Expression RegulationHumansLymphocyte ActivationMicroRNAsMultigene FamilyPrecursor Cells, B-LymphoidProteomeProteomicsMicroRNAsMIRN23a microRNA, humanMIRN24 microRNA, humanMIRN27 microRNA, humanProteomeclusteriTRAQmicroRNAmiR-23amiR-24miR-27a

Identifiers

PMID27028342
PMCPMC5305806
OpenAlexW2320162489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.